The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

USPSTF breast cancer screening guidelines are clear, concise; now let’s address gaps in quality

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This week, the U.S. Preventive Services Task Force published a new draft guideline on breast cancer screening.1 The task force is considered the most rigorous and orthodox authority on the interpretation and application of the medical literature.The panel is widely respected for its expertise in epidemiology, screening, clinical trials interpretation, and structured reviews of the...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

UF Health Cancer Center rolls out mobile cancer screening vehicle

UF Health officials and supporters gathered Wednesday to unveil the UF Health Cancer Center’s Mobile Cancer Screening Connector, which will take cancer screening care to a 23-county area in North Florida. UF Health photo by Nate GuidryThe University of Florida Health Cancer Center launched a 40-foot-long mobile cancer screening bus that will expand access to cancer screenings and essential health care services, including 3D mammograms and cervical, colon, and prostate cancer screenings.
Clinical Roundup

Medicaid expansion may improve cancer care and survival for people with HR-negative, HER2-positive breast cancer

New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account